Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
7,519.12
(
0.61%
)
US TECH 100
29,229.20
(
1.84%
)
Dow Jones
50,461.68
(
-0.23%
)
Brent Oil
95.77
(
-1.26%
)
Bitcoin
75,782.35
(
-0.08%
)
News Focus
News Focus
Post# of 19309
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (3) Keep Next 10 Report Keyboard Shortcuts
Replies (3) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 123024
Boards Moderated 9
Alias Born 09/05/2002

DewDiligence

Member Level

Re: go seek post# 15659

Tuesday, 12/02/2008 9:26:48 PM

Tuesday, December 02, 2008 9:26:48 PM

Post# of 19309
>“LEO has confirmed that there are no safety or efficacy issues with the ATryn product, either commercially or in the phase II DIC clinical study.”<

This excerpt does not pass the smell test, IMO. I think it’s a near certainty that Leo saw something in the phase-2 data that was not to its liking.


“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (3) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (3) Next 10 Prev Next

Trade Smarter with Thousands

Leverage decades of market experience shared openly.

Join Now